Patent · US Active

Selective histone deactylase 6 inhibitors

US9751832B2 · kind B2 · utility

7Cited by

1References

7Claims

0Family size

Assignees

Inventors

Eduardo M. Sotomayor · Tampa, US
Joel Bergman · Chicago, US
Alan P. Kozikowski · Princeton, US
Alejandro V. Villagra · Tampa, US
Karrune V. Woan · Gainesville, US

Key dates

Filing date	Jul 30, 2014
Grant date	Sep 5, 2017
Priority date	—
Expiry date	Jul 30, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D295/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Specifically, the disclosed subject matter relates to compounds having activity as selective HDAC6 inhibitors, methods of making and using the compounds, and compositions comprising the compounds. In still further aspects, the disclosed subject matter relates to methods for treating oncological disorders in a patient. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.